Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

SVB ups scPharmaceuticals on FDA approval of Furoscix

SVB Securities upgraded scPharmaceuticals (NASDAQ:SCPH) to “outperform” from “market perform” and raised its price target to $11 from $6 after FDA approval of Furoscix for treatment of congestion in chronic heart...

October 11, 2022

Developments

Ripple Therapeutics signs licensing agreement for China with CS Pharmaceuticals

Closely held Ripple Therapeutics signed an exclusive licensing agreement for the Chinese rights to its lead product, IBE-814, with CS Pharmaceuticals, a British-based company focused on the development and...

October 11, 2022

Developments

Oramed unit posts positive preliminary Phase 1 oral COVID-19 vaccine data

Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) subsidiary, Oravax Medical, reported positive preliminary data from its Phase 1 trial of an oral COVID-19 vaccine candidate. Oravax Medical is developing oral vaccines that...

October 7, 2022

Developments

FDA clears Boston Cell Standards’ IHControls panel in breast cancer

Closely held Boston Cell Standards received 510(k) clearance from the FDA for its IHControls panel (HER2/ER/PR) for evaluating breast cancers, representing a first-in-category regulatory approval. IHControls are the...

October 6, 2022

Developments

FDA clears Annovis Bio for Phase 2/3 AD study

The FDA approved the development plan and study protocol for Annovis Bio (NYSE:ANVS) to proceed with a Phase 2/3 clinical study of buntanetap in moderate Alzheimer’s Disease (AD). In a statement, Maria...

October 6, 2022

Developments

Sigyn Therapeutics files U.S. patent entitled “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”

Sigyn Therapeutics (OTCQB:SIGY) filed a provisional patent application entitled, “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity,” with the United States Patent and Trademark Office. Cancer is...

October 6, 2022

Markets

HCW starts Eyenovia at buy; PT $12

H.C. Wainwright launched coverage of Eyenovia (NASDAQ:EYEN) with a “buy” rating and $12 price target. The stock closed at $2.15 on Oct. 4. Eyenovia is developing ophthalmic therapeutics based on the company’s microdose...

October 5, 2022

Executive Moves

Sigyn Therapeutics strengthens board with 3 appointments

Sigyn Therapeutics (OTCQB:SIGY) appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its board, effective Oct. 10, 2022. “As we transition toward the next phase of our clinical endeavors, it is an opportune...

October 4, 2022

Markets

Cantor starts Irwin Naturals at OW; PT $7

Cantor Fitzgerald initiated coverage of Irwin Naturals (OTCQB:IWINF) with and “overweight” rating and a December 2023 price target of $7. The stock closed at $1.51 on Oct. 3. Irwin Naturals, a company with a 28-year...

October 4, 2022

Markets

Clene shares down 29% after Phase 2 ALS trial fails

Shares of Clene (NASDAQ:CLNN) tumbled 29% after its lead drug candidate, CNM-Au8, an investigational gold nanocrystal suspension, missed key endpoints in a platform study in amyotrophic lateral sclerosis (ALS), a...

October 3, 2022

Developments

FDA clears Tonix IND in major depressive disorder

The FDA approved Tonix Pharmaceuticals’ (NASDAQ:TNXP) IND application to support a Phase 2 clinical trial with TNX-601 ER, a once-daily formulation of tianeptine as a potential treatment for major depressive disorder...

October 3, 2022

Markets

Maxim ups Fennec PT to $15 on PEDMARK approval

Maxim Group raised its price target for Fennec Pharmaceuticals (NASDAQ:FENC) to $15 from $10, and maintained its “buy” rating, after FDA approval of PEDMARK, its formulation of sodium thiosulfate for the prevention of...

September 29, 2022

Subscribe